Fluoxetine disposition

Schenker, S., Bergstrom, R.F., Wolen, R.L., and Lemberger, L. (1988) Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther 44 353-359. 

Hamelin, B. A., Turgeon, J., Vallee, F. etal. (1996). The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin. Pharmacol. Ther., 60, 512-21. 

Bertelsen, K.M., Venkatakrishnan, K., Von Moltke, L.L., Obach, R.S. and Greenblatt, D.J. (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine comparison with fluoxetine and quinidine. Drug Metabolism and Disposition The Biolo cal Fate of Chemicals, 31, 289-293. 

Lemberger L, Bergstrom RF, Wolen RL, FaridNA,EnasGG, Aronoff GR. Fluoxetine clinical pharmacology and physiologic disposition. J C w Psychiatry (1985) 46,14-19. 

Carson SW, Letrent KJ, Kotlyar M, Foose G, Tancer ME. Lack of fluoxetine effect on prednisolone disposition and cortisol suppression. Pharmacotherapy (2004) 24,482-7. 

---